Spots Global Cancer Trial Database for al amyloidosis
Every month we try and update this database with for al amyloidosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis | NCT04392960 | AL Amyloidosis | [18F]Florbetabe... | 18 Years - | IRCCS Policlinico S. Matteo | |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | NCT06365060 | Smoldering Mult... | 40 Years - | Tufts Medical Center | ||
| Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | NCT04270175 | Amyloid AL Amyloidosis Refractory AL A... | Daratumumab SC Pomalidomide Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| Screening to Improve Survival in AL Amyloidosis | NCT04615572 | Smoldering Mult... Monoclonal Gamm... | 60 Years - | Tufts Medical Center | ||
| Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | NCT04612582 | Immunoglobulin ... | Thalidomide Cyclophosphamid... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | NCT05199337 | Amyloidosis AL Amyloidosis | ZN-d5 | 18 Years - | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | |
| Screening to Improve Survival in AL Amyloidosis | NCT04615572 | Smoldering Mult... Monoclonal Gamm... | 60 Years - | Tufts Medical Center | ||
| Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis | NCT00344526 | Primary Systemi... | Melphalan Dexamethasone Autologous stem... | 18 Years - 70 Years | University Hospital, Limoges | |
| Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial | NCT02207556 | Primary Systemi... | Doxycycline | 18 Years - | Medical College of Wisconsin | |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | NCT06022939 | AL Amyloidosis | Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ... | 18 Years - | SWOG Cancer Research Network | |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | NCT03315026 | Multiple Myelom... AL Amyloidosis | Siltuximab The M.D. Anders... | 60 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| A Registry of AL Amyloidosis (ReAL) | NCT04839003 | AL Amyloidosis | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | ||
| A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA) | NCT06205953 | AL Amyloidosis | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | ||
| Quality of Life (QOL) Registry for Patients With AL Amyloidosis | NCT02574676 | AL Amyloidosis Amyloidosis | non-interventio... | 18 Years - | Prothena Biosciences Ltd. | |
| Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis | NCT03431896 | Amyloidosis Amyloid Amyloid Neuropa... Amyloid Cardiom... Amyloid - Prima... Transthyretin A... AL Amyloidosis | - | The Cleveland Clinic | ||
| A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | NCT04304144 | AL Amyloidosis | CAEL-101 SoC: cyclophosp... Daratumumab | 18 Years - | Alexion Pharmaceuticals, Inc. | |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | NCT06022939 | AL Amyloidosis | Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ... | 18 Years - | SWOG Cancer Research Network | |
| Amyloidosis Incidence in High-Risk Cardiac Device Patients | NCT06186167 | Amyloid Cardiac Amyloid... Amyloidosis Car... Systemic Amyloi... AL Amyloidosis Infiltrative Ca... ATTR Amyloidosi... | Chest Wall Fat ... | 40 Years - | Midwest Heart & Vascular Specialists | |
| Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib | NCT02489500 | AL Amyloidosis | Bortezomib Melphalan Neupogen Stem Cell Colle... Stem cell infus... | 18 Years - | Boston Medical Center | |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | NCT06022939 | AL Amyloidosis | Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ... | 18 Years - | SWOG Cancer Research Network | |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | NCT03236792 | AL Amyloidosis | Ixazomib Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Registry of AL Amyloidosis (ReAL) | NCT04839003 | AL Amyloidosis | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | ||
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | NCT04847453 | AL Amyloidosis | Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Dexamethasone Ixazomib Citrat... Magnetic Resona... Positron Emissi... Transabdominal ... Venetoclax X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Study in Subjects With Light Chain (AL) Amyloidosis | NCT03154047 | AL Amyloidosis | NEOD001 | 18 Years - | Prothena Biosciences Ltd. | |
| A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | NCT04115956 | AL Amyloidosis | Melphalan-Flufe... Dexamethasone | 18 Years - | Oncopeptides AB | |
| Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis | NCT04754945 | AL Amyloidosis | Bortezomib Cyclophosphamid... Dexamethasone Isatuximab | 18 Years - | Emory University | |
| Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | NCT02613182 | AL Amyloidosis | NEOD001 | - | Prothena Biosciences Ltd. | |
| Promoting Diagnosis and Management of AL in Italy (ProDigALIty) | NCT06383143 | AL Amyloidosis Smoldering Mult... Monoclonal Gamm... | no intervention | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | |
| Screening to Improve Survival in AL Amyloidosis | NCT04615572 | Smoldering Mult... Monoclonal Gamm... | 60 Years - | Tufts Medical Center | ||
| Promoting Diagnosis and Management of AL in Italy (ProDigALIty) | NCT06383143 | AL Amyloidosis Smoldering Mult... Monoclonal Gamm... | no intervention | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | NCT03236792 | AL Amyloidosis | Ixazomib Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Amyloidosis Incidence in High-Risk Cardiac Device Patients | NCT06186167 | Amyloid Cardiac Amyloid... Amyloidosis Car... Systemic Amyloi... AL Amyloidosis Infiltrative Ca... ATTR Amyloidosi... | Chest Wall Fat ... | 40 Years - | Midwest Heart & Vascular Specialists | |
| Ixazomib Maintenance Study in Patients With AL Amyloidosis | NCT03618537 | AL Amyloidosis | Ixazomib Dexamethasone | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource | NCT01408225 | Plasma Cell Dys... Monoclonal Gamm... AL Amyloidosis Multiple Myelom... | tissue banking | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | NCT04984330 | Amyloid Amyloidosis AL Amyloidosis | Selinexor Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis | NCT01222260 | AL Amyloidosis | Bendamustine Dexamethasone | 18 Years - | Columbia University | |
| A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab | NCT05277493 | AL Amyloidosis | 18 Years - | Peking Union Medical College Hospital | ||
| A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe | NCT04937777 | AL Amyloidosis | 18 Years - | Stichting European Myeloma Network | ||
| A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis | NCT02545907 | Amyloidosis | Carfilzomib Thalidomide Dexamethasone | 18 Years - | University College, London | |
| A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | NCT04304144 | AL Amyloidosis | CAEL-101 SoC: cyclophosp... Daratumumab | 18 Years - | Alexion Pharmaceuticals, Inc. | |
| A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | NCT04617925 | AL Amyloidosis | Belantamab mafo... | 18 Years - | Stichting European Myeloma Network | |
| Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | NCT01998503 | Amyloidosis | Bortezomib dexamethasone filgrastim autologous hema... Melphalan | 18 Years - 65 Years | Nanjing University School of Medicine | |
| Amyloidosis Incidence in High-Risk Cardiac Device Patients | NCT06186167 | Amyloid Cardiac Amyloid... Amyloidosis Car... Systemic Amyloi... AL Amyloidosis Infiltrative Ca... ATTR Amyloidosi... | Chest Wall Fat ... | 40 Years - | Midwest Heart & Vascular Specialists | |
| High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease | NCT01531751 | Primary Amyloid... | High Cut-off He... Chemotherapy | 18 Years - | IRCCS Policlinico S. Matteo | |
| Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy | NCT05066607 | AL Amyloidosis | Isatuximab | 18 Years - | Intergroupe Francophone du Myelome | |
| Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | NCT05898646 | AL Amyloidosis | Bone Marrow Asp... Daratumumab Echocardiograph... Questionnaire A... X-Ray Imaging Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | NCT01998503 | Amyloidosis | Bortezomib dexamethasone filgrastim autologous hema... Melphalan | 18 Years - 65 Years | Nanjing University School of Medicine | |
| Allo SCT in Amyloidosis Non-interventional Study | NCT02257905 | AL Amyloidosis | 18 Years - 60 Years | European Society for Blood and Marrow Transplantation | ||
| Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | NCT01707264 | Primary Amyloid... | NEOD001 | 18 Years - | Prothena Biosciences Ltd. | |
| Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis | NCT05184088 | Cardiac Amyloid... AL Amyloidosis ATTR Amyloidosi... | [18F]florbetabe... | 18 Years - | Life Molecular Imaging SA | |
| Autologous Stem Cell Transplantation for Patients With AL Amyloidosis | NCT04210791 | AL Amyloidosis Plasma Cell Dys... | 18 Years - 75 Years | Nanjing University School of Medicine | ||
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis | NCT04504825 | AL Amyloidosis | CAEL-101 Placebo cyclophosphamid... | 18 Years - | Alexion Pharmaceuticals, Inc. | |
| A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | NCT04617925 | AL Amyloidosis | Belantamab mafo... | 18 Years - | Stichting European Myeloma Network | |
| Optimize First-line Treatment for AL Amyloidosis With t (11; 14) | NCT06192979 | Amyloidosis; Sy... AL Amyloidosis | Daratumumab Bortezomib Dexamethasone Venetoclax | - | Peking University People's Hospital | |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | NCT05451771 | AL Amyloidosis | Venetoclax Oral... FISH assay Venetoclax Oral... Dexamethasone O... Dexamethasone O... Daratumumab Inj... Bendamustine Pomalidomide Ixazomib Venetoclax MTD ... | 18 Years - | Columbia University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
